Ask AI
ProCE Banner Activity

Interactive EU-Focused Tool to Guide the Management of BTK Inhibitor–Related Adverse Events in MCL

Tool

Get recommendations from 2 European Union (EU) experts on the management BTK inhibitor–related adverse events in MCL for your specific patient case using this interactive decision support tool.

Released: June 25, 2025

Expiration: December 24, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Faculty Disclosure

Primary Author

Georg Hess, MD: consultant/speaker: AbbVie, ADC, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Lilly, Merck Sharp & Dohme, Miltenyi Biotech, Novartis, Pierre Fabre, Roche, Sobi; researcher (paid to institution): AbbVie, Gilead/Kite, Janssen, Lilly; other financial or material support: Incyte, Janssen, Pierre Fabre.

Carlo Visco, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Gentili, Incyte, Janssen, Kite/Gilead, Kyowa Kirin, Lilly, Novartis, Pfizer, Roche, Servier.